Departments of *Neurology §Radiology ¶Bioengineering ‡The Charles F. and Joanne Knight Alzheimer's Disease Research Center ∥The Hope Center, Washington University in St Louis †Saint Louis College of Pharmacy, Saint Louis, MO.
Alzheimer Dis Assoc Disord. 2014 Apr-Jun;28(2):122-7. doi: 10.1097/WAD.0b013e318299d096.
This work is to determine whether apolipoprotein E (APOE) genotype modulates the effect of cholinesterase inhibitor (ChEI) treatment on resting state functional connectivity magnetic resonance imaging (rs-fcMRI) in patients with Alzheimer disease (AD). We retrospectively studied very mild and mild AD participants who were treated (N=25) or untreated (N=19) with ChEIs with respect to rs-fcMRI measure of 5 resting state networks (RSNs): default mode, dorsal attention (DAN), control (CON), salience (SAL), and sensory motor. For each network, a composite score was computed as the mean of Pearson correlations between pairwise time courses extracted from areas comprising this network. The composite scores were analyzed as a function of ChEI treatment and APOE ε4 allele. Across all participants, significant interactions between ChEI treatment and APOE ε4 allele were observed for all 5 RSNs. Within APOE ε4 carriers, significantly greater composite scores were observed in the DAN, CON, and SAL for treated compared with untreated participants. Within APOE ε4 noncarriers, treated and untreated participants did not have significantly different composite scores for all RSNs. These data suggest that APOE genotype affects the response to ChEI using rs-fcMRI. Rs-fcMRI may be useful for assessing the therapeutic effect of medications in AD clinical trials.
这项工作旨在确定载脂蛋白 E(APOE)基因型是否调节胆碱酯酶抑制剂(ChEI)治疗对阿尔茨海默病(AD)患者静息状态功能磁共振成像(rs-fcMRI)的影响。我们回顾性研究了接受(N=25)或未接受(N=19)ChEI 治疗的非常轻度和轻度 AD 参与者的 rs-fcMRI 测量值,涉及 5 个静息状态网络(RSN):默认模式、背侧注意(DAN)、控制(CON)、突显(SAL)和感觉运动。对于每个网络,计算了一个复合得分,作为从组成该网络的区域提取的成对时间序列的 Pearson 相关系数的平均值。复合得分作为 ChEI 治疗和 APOE ε4 等位基因的函数进行分析。在所有参与者中,在所有 5 个 RSN 中均观察到 ChEI 治疗和 APOE ε4 等位基因之间存在显著的相互作用。在 APOE ε4 携带者中,与未接受治疗的参与者相比,接受治疗的参与者的 DAN、CON 和 SAL 的复合得分明显更高。在 APOE ε4 非携带者中,接受治疗和未接受治疗的参与者在所有 RSN 中均未显示出明显不同的复合得分。这些数据表明,APOE 基因型影响使用 rs-fcMRI 的 ChEI 反应。rs-fcMRI 可能有助于评估 AD 临床试验中药物的治疗效果。